Mapping the Global Landscape of Cancer Research: Key Trends from the Nature Index

How is the global scientific community distributing its resources and efforts in the fight against cancer? A detailed analysis of cancer-related publications in the Nature Index for the period from January 2021 to August 2025 provides a high-resolution snapshot of the field’s leaders, top-studied malignancies, and rising areas of interest.

From the rise of new research powerhouses to the shifting focus of top-tier biomedical institutions, this index dataset—compiled by analyst Aayush Kagathra and visualized by Bec Crew and Tanner Maxwell—reveals a highly concentrated, dynamic global ecosystem. In this post, we unpack the major trends in global cancer research, cross-reference them with underlying molecular genomics, and discuss what these numbers tell us about the future of oncology.

1. The Global Power Balance: A US-China Duopoly

A breakdown of country and territory Share in cancer-related articles reveals that the United States and China are in a dead heat, dominating the highest-tier natural and health sciences journals.

Together, the US and China account for approximately 60% of the global cancer Share tracked by the Nature Index. The next closest contributor, the United Kingdom, represents just 4.55% of the total Share.

*Data covers the period from January 2021 to August 2025.

This duopoly reflects a broader regional shift. The Asia-Pacific region leads globally with 13,568.1 Share points, followed closely by North America (12,170.9) and Europe (7,221.0). In contrast, regions like South America (104.1) and Africa (47.1) continue to represent a very small fraction of the top-tier publication volume, highlighting a persistent disparity in global research infrastructure and funding.

The “Strong Focus” Locations

It is not just about absolute volume; some countries prioritize cancer research as a disproportionately large part of their total scientific output. For countries like Singapore (299.0 Share), the Netherlands, the US, Canada, and Taiwan (208.3 Share), cancer research accounts for roughly 10% of their total output across all natural and health sciences tracked by the Index.

2. Leading Cancer Types: Why Breast Cancer Dominates

Among the top 10 cancer types by research output, breast cancer holds an overwhelming lead, outpacing second-place lung cancer by more than 1,500 Share points.

Nature Index Share by Cancer Type (2021–2025)
==============================================
1. Breast cancer           ████████████████████████ [Leads by >1,500 Share points]
2. Lung cancer             ██████████████
3. Colorectal cancer       ██████████
4. Leukaemia               ████████
5. Melanoma                ███████
6. Liver cancer            ██████
7. Brain tumour            █████
8. Pancreatic cancer       ████
9. Prostate cancer         ████
10. Non-Hodgkin's lymphoma ███

The Genomic Drivers of Research

Why does breast cancer command such a massive portion of the scientific spotlight?

1. Prevalence and Subtype Complexity: Breast cancer is the most diagnosed cancer globally. Clinically, it is highly heterogeneous, spanning hormone-receptor-positive (HR+), HER2-amplified, and triple-negative breast cancers (TNBC), each requiring distinct therapeutic paradigms.
2. Genomic Instability & Reassembly: As explored in our post on Shattered Chromosomes: Understanding Chromothripsis and Genome Rearrangement Models, breast cancers are heavily driven by complex copy-number changes and structural variations. Focal amplifications of critical oncogenes like CCND1 and MDM2, as well as deletions of tumor suppressors like BRCA1 and BRCA2, are frequently associated with catastrophic chromosome shattering events.
3. Advanced Transcriptomics: To parse this heterogeneity, researchers rely on deep molecular characterization. Profiling techniques like RNA-seq data analysis and long-read transcriptome profiling (ONT direct RNA Data Analysis using Dorado) have become workhorses in breast cancer labs to define novel splicing isoforms and chimeric fusion genes.

In contrast, melanoma (#5) and lung cancer (#2) are frequently the focus of immunological research. Melanoma has a high tumor mutational burden (TMB) due to UV damage, making it the premier model for immune checkpoint inhibitor trials. Conversely, pancreatic cancer (#8) and brain tumours (#7) remain notoriously difficult to treat, driving intensive basic biology research despite lower absolute publication counts than breast or lung cancer.

3. Rising Fast: Cancers Gaining Momentum

While breast and lung cancers maintain the highest absolute volume, other cancer types are experiencing rapid research acceleration. The Nature Index highlights two patterns of growth: absolute increases vs. percentage increases.

A. The Liver Cancer Surge

Liver cancer is the standout performer of the 2021–2025 period. It is one of the top six fastest-rising cancers by absolute increase, and it jumped by more than 150% in percentage growth over the period. This is particularly remarkable because liver cancer did not start from a low baseline; it already had a significant Share in 2021.

This surge is largely driven by:

• East Asian Research Focus: The high prevalence of Hepatitis B/C and hepatocellular carcinoma (HCC) in China and East Asia has led to a massive expansion of liver cancer research in regional hubs.
• Immunotherapy Breakthroughs: The success of combination immunotherapies (e.g., Atezolizumab + Bevacizumab) has opened up new avenues for clinical and translational research.

B. Percentage Growth Leaders

Most of the cancers with the highest percentage increases between 2021 and 2025 started from a lower output base:

1. Liver cancer (>150% increase)
2. Stomach (gastric) cancer
3. Cervical cancer
4. Oral cavity and lip cancer
5. Oesophageal cancer
6. Head and neck cancer

Many of these malignancies (stomach, oesophageal, and nasopharyngeal/head and neck cancers) exhibit high incidence rates in Asian countries, aligning with the dramatic rise of Chinese institutions in the Nature Index.

4. The Institutional Vanguard: A Spatial Matrix

Which institutions are steering the direction of global oncology? By mapping the leading institutions against their Share in specific cancer types, we can see where different specialties are concentrated.

Harvard University leads the world with 1,027.7 Share points, followed by the Chinese Academy of Sciences (CAS) at 663.0. Interestingly, the University of Toronto is one of the very few institutions outside the United States and China to crack the top ranks.

Below is the research footprint of the leading 14 global institutions across the main cancer subtypes:

Institutional Insights

• Harvard’s Breadth: Harvard maintains an exceptional lead across almost every major category, showing particularly strong dominance in breast cancer (110.1 Share), lung cancer (97.4), pancreatic cancer (63.0), and brain tumours (44.4).
• China’s Breast Cancer Focus: Both the Chinese Academy of Sciences (79.3) and Fudan University (65.6) exhibit an intense concentration of research in breast cancer.
• Prostate Cancer Discrepancies: Interestingly, the Chinese Academy of Sciences shows a highly elevated Share in prostate cancer (49.2), significantly outperforming Harvard (8.8) and NIH (19.3) in this category.
• MD Anderson’s Specialized Strength: As a dedicated cancer center, MD Anderson has a very high Share relative to its size, leading in lung cancer (57.7) and leukemia (38.7).

5. Integrating the Data: The Role of Meta-Analysis

With thousands of high-quality papers published annually across these top institutions, synthesizing this mountain of literature becomes a major challenge. How do clinicians and policymakers translate these disparate Nature Index studies into actionable clinical guidelines?

This is where the statistical framework of meta-analysis becomes critical. As detailed in our guide on Introduction to Meta-analysis: fixed-effect model and random-effect model, meta-analyses allow researchers to:

• Pool effect sizes (e.g., hazard ratios, odds ratios) from multiple clinical trials or genomic association studies.
• Quantify and control for inter-study heterogeneity (crucial when combining datasets from different populations or sequencing platforms).
• Identify publication bias and establish the “true” clinical efficacy of novel therapeutic agents.

As the absolute output of oncology research continues to accelerate—particularly in fast-rising subtypes like liver and stomach cancer—robust meta-analytic synthesis will be more important than ever to separate signal from noise.

6. Looking Ahead: What’s Next?

The Nature Index data for 2021–2025 demonstrates that the global fight against cancer is scaling rapidly, led by a competitive race between the US and China.

As we move forward, several factors are likely to reshape this landscape:

1. The Single-Cell and Spatial Revolution: Standard bulk RNA-seq is increasingly giving way to single-cell RNA-seq and spatial transcriptomics, allowing researchers to study the tumor microenvironment (TME) with cellular resolution.
2. Long-Read Genotyping: Resolving complex genomic reorganizations—like the shattered chromosomes of chromothripsis—will increasingly rely on long-read sequencing technologies to span repetitive regions and identify structural variations.
3. AI in Oncology: The integration of deep learning and probabilistic graphical models is shifting from basic diagnostic imaging to predicting patient drug response based on multi-omics data.

The institutions that lead the next iteration of the Nature Index will likely be those that successfully bridge the gap between massive multi-omics datasets, advanced computational modeling, and clinical translation.

Data Sources

• All publication Share data is sourced from the Nature Index (Vol 652, 16 April 2026).
• Coverage period: January 2021 to August 2025.